Beijing Biostar Pharmaceuticals Co Ltd
Company Profile
Business description
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
Contact
22 Ronghua Middle Road
Suite 1202, Tower B, Yicheng Fortune Center
Beijing Economic-Technological Development Area
Beijing100176
CHNT: +86 1067864938
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
stocks
Telstra earnings: No need to get hysterical over mobile
stocks
Market Minute: RBA cuts rates again, US CPI data released
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,233.50 | 21.40 | 0.23% |
| CAC 40 | 7,884.05 | 39.40 | -0.50% |
| DAX 40 | 24,314.77 | 44.53 | -0.18% |
| Dow JONES (US) | 44,911.82 | 34.30 | -0.08% |
| FTSE 100 | 9,157.74 | 18.84 | 0.21% |
| HKSE | 25,176.85 | 93.22 | -0.37% |
| NASDAQ | 21,629.77 | 6.80 | 0.03% |
| Nikkei 225 | 43,714.31 | 336.00 | 0.77% |
| NZX 50 Index | 12,970.64 | 81.26 | 0.63% |
| S&P 500 | 6,449.15 | 0.65 | -0.01% |
| S&P/ASX 200 | 8,959.30 | 20.70 | 0.23% |
| SSE Composite Index | 3,728.03 | 31.26 | 0.85% |